Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2014, Article ID 273506, 7 pages
http://dx.doi.org/10.1155/2014/273506
Review Article

Current Treatment of Toxoplasma Retinochoroiditis: An Evidence-Based Review

1Texas Tech University, Health Sciences Center, Paul L. Foster School of Medicine, El Paso, TX 79905, USA
2Cullen Eye Institute, Baylor College of Medicine, 1977 Butler Boulevard, Houston, TX 77030, USA

Received 1 June 2014; Accepted 23 July 2014; Published 13 August 2014

Academic Editor: Thomas A. Albini

Copyright © 2014 Meredith Harrell and Petros E. Carvounis. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. N. Holland, “Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease,” American Journal of Ophthalmology, vol. 136, no. 6, pp. 973–988, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. G. N. Holland, “Ocular toxoplasmosis: a global reassessment: Part II: disease manifestations and management,” The American Journal of Ophthalmology, vol. 137, no. 1, pp. 1–17, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. M. B. Balasundaram, R. Andavar, M. Palaniswamy, and N. Venkatapathy, “Outbreak of acquired ocular toxoplasmosis involving 248 patients,” Archives of Ophthalmology, vol. 128, no. 1, pp. 28–32, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. E. M. Dodds, G. N. Holland, M. R. Stanford et al., “Intraocular inflammation associated with ocular toxoplasmosis: relationships at initial examination,” American Journal of Ophthalmology, vol. 146, no. 6, pp. 856.e2–865.e2, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. N. J. S. London, A. Hovakimyan, L. D. P. Cubillan, C. D. Siverio Jr., and E. T. Cunningham Jr., “Prevalence, clinical characteristics, and causes of vision loss in patients with ocular toxoplasmosis,” European Journal of Ophthalmology, vol. 21, no. 6, pp. 811–819, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. L. E. H. Bosch-Driessen, T. T. J. M. Berendschot, J. V. Ongkosuwito, and A. Rothova, “Ocular toxoplasmosis: clinical features and prognosis of 154 patients,” Ophthalmology, vol. 109, no. 5, pp. 869–878, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. M. R. Stanford, E. A. Tomlin, O. Comyn, K. Holland, and C. Pavesio, “The visual field in toxoplasmic retinochoroiditis,” British Journal of Ophthalmology, vol. 89, no. 7, pp. 812–814, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. S. J. Kim, I. U. Scott, G. C. Brown et al., “Interventions for toxoplasma retinochoroiditis: a report by the american academy of ophthalmology,” Ophthalmology, vol. 120, no. 2, pp. 371–378, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. E. S. Perkins, P. B. Schofield, and C. H. Smith, “Treatment of uveitis with pyrimethamine (daraprim),” The British Journal of Ophthalmology, vol. 40, no. 10, pp. 577–586, 1956. View at Publisher · View at Google Scholar · View at Scopus
  10. G. W. Tate and R. G. Martin, “Clindamycin in the treatment of human ocular toxoplasmosis,” Canadian Journal of Ophthalmology, vol. 12, no. 3, pp. 188–195, 1977. View at Google Scholar · View at Scopus
  11. J. G. Ferguson Jr., “Clindamycin therapy for toxoplasmosis,” Annals of Ophthalmology, vol. 13, no. 1, pp. 95–100, 1981. View at Google Scholar · View at Scopus
  12. H. Guldstein, “Clindamycin and sulphonamides in the treatment of ocular toxoplasmosis,” Acta Ophthalmologica, vol. 61, no. 1, pp. 51–57, 1983. View at Google Scholar · View at Scopus
  13. J. V. Cassady, J. W. Bahler, and M. V. Hinken, “Spiramycin for toxoplasmosis,” The American Journal of Ophthalmology, vol. 57, no. 2, pp. 227–235, 1964. View at Google Scholar · View at Scopus
  14. A. Yazici, P. Ç. Ozdal, I. Taskintuna, S. Kavuncu, and G. Koklu, “Trimethoprim/sulfamethoxazole and azithromycin combination therapy for ocular toxoplasmosis,” Ocular Immunology and Inflammation, vol. 17, no. 4, pp. 289–291, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Rothova, L. E. H. Bosch-Driessen, N. H. van Loon, and W. F. Treffers, “Azithromycin for ocular toxoplasmosis,” British Journal of Ophthalmology, vol. 82, no. 11, pp. 1306–1308, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. E. M. Opremcak, D. K. Scales, and M. R. Sharpe, “Trimethoprim-sulfamethoxazole therapy for ocular toxoplasmosis,” Ophthalmology, vol. 99, no. 6, pp. 920–925, 1992. View at Publisher · View at Google Scholar · View at Scopus
  17. P. A. Pearson, A. R. Piracha, H. A. Sen, and G. J. Jaffe, “Atovaquone for the treatment of toxoplasma retinochoroiditis in immunocompetent patients,” Ophthalmology, vol. 106, no. 1, pp. 148–153, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. R. V. Fajardo, F. P. Furgiuele, and I. H. Leopold, “Treatment of toxoplasmosis uveitis,” Archives of Ophthalmology, vol. 67, pp. 712–720, 1962. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Nolan and E. S. Rosen, “Treatment of active toxoplasmic retino-choroiditis,” British Journal of Ophthalmology, vol. 52, no. 5, pp. 396–399, 1968. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Rothova, H. J. Buitenhuis, C. Meenken et al., “Therapy of ocular toxoplasmosis,” International Ophthalmology, vol. 13, no. 6, pp. 415–419, 1989. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Rothova, C. Meenken, H. J. Buitenhuis et al., “Therapy for ocular toxoplasmosis,” American Journal of Ophthalmology, vol. 115, no. 4, pp. 517–523, 1993. View at Google Scholar · View at Scopus
  22. T. E. Acers, “Toxoplasmic retinochoroiditis: a double blind therapeutic study,” Archives of Ophthalmology, vol. 71, pp. 58–62, 1964. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Soheilian, M. Sadoughi, M. Ghajarnia et al., “Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis,” Ophthalmology, vol. 112, no. 11, pp. 1876–1882, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. L. H. Bosch-Driessen, F. D. Verbraak, M. S. A. Suttorp-Schulten et al., “A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis,” The American Journal of Ophthalmology, vol. 134, no. 1, pp. 34–40, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Balaskas, J. Vaudaux, N. Boillat-Blanco, and Y. Guex-Crosier, “Azithromycin versus sulfadiazine and pyrimethamine for non-vision-threatening toxoplasmic retinochoroiditis: a pilot study,” Medical Science Monitor, vol. 18, no. 5, pp. 296–302, 2012. View at Google Scholar · View at Scopus
  26. B. Iaccheri, T. Fiore, T. Papadaki et al., “Adverse drug reactions to treatments for ocular toxoplasmosis: a retrospective chart review,” Clinical Therapeutics, vol. 30, no. 11, pp. 2069–2074, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Khalili, A. Soudbakhsh, and A. H. Talasaz, “Severe hepatotoxicity and probable hepatorenal syndrome associated with sulfadiazine,” The American Journal of Health-System Pharmacy, vol. 68, no. 10, pp. 888–892, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Yan, B. Huang, G. Liu et al., “Meta-analysis of prevention and treatment of toxoplasmic encephalitis in HIV-infected patients,” Acta Tropica, vol. 127, no. 3, pp. 236–244, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. K. F. Tabbara, J. Dy-Liacco, R. A. Nozik, G. R. O'Connor, and H. J. Blackman, “Clindamycin in chronic toxoplasmosis: effect of periocular injections on recoverability of organisms from healed lesions in the rabbit eye,” Archives of Ophthalmology, vol. 97, no. 3, pp. 542–544, 1979. View at Publisher · View at Google Scholar · View at Scopus
  30. K. F. Tabbara, R. A. Nozik, and G. R. O'Connor, “Clindamycin effects on experimental ocular toxoplasmosis in the rabbit,” Archives of Ophthalmology, vol. 92, no. 3, pp. 244–247, 1974. View at Publisher · View at Google Scholar · View at Scopus
  31. C. E. Martinez, D. Zhang, M. D. Conway, and G. A. Peyman, “Successful management of ocular toxoplasmosis during pregnancy using combined intraocular clindamycin and dexamethasone with systemic sulfadiazine,” International Ophthalmology, vol. 22, no. 2, pp. 85–88, 1998. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Sobrin, L. I. Kump, and C. S. Foster, “Intravitreal clindamycin for toxoplasmic retinochoroiditis,” Retina, vol. 27, no. 7, pp. 952–957, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. A. F. Lasave, M. Daz-Llopis, C. Muccioli, R. Belfort Jr., and J. F. Arevalo, “Intravitreal clindamycin and dexamethasone for zone 1 toxoplasmic retinochoroiditis at twenty-four months,” Ophthalmology, vol. 117, no. 9, pp. 1831–1838, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Soheilian, A. Ramezani, A. Azimzadeh et al., “Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis,” Ophthalmology, vol. 118, no. 1, pp. 134–141, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. N. Baharivand, A. Mahdavifard, and R. F. Fouladi, “Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: a prospective randomized clinical trial,” International Ophthalmology, vol. 33, no. 1, pp. 39–46, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. P. Kim, N. Younan, and M. T. Coroneo, “Hypersensitivity reaction to intravitreal clindamycin therapy,” Clinical and Experimental Ophthalmology, vol. 30, no. 2, pp. 147–148, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. H. F. Spalter, C. J. Campbell, K. S. Noyori, M. C. Rittler, and C. J. Koester, “Prophylactic photocoagulation of recurrent toxoplasmic retinochoroiditis,” Archives of Ophthalmology, vol. 75, no. 1, pp. 21–31, 1966. View at Publisher · View at Google Scholar · View at Scopus
  38. T. Desmettre, P. Labalelette, B. Fortier, S. Mordon, and G. Constantinides, “Laser photocoagulation around the foci of toxoplasma retinochoroiditis: a descriptive statistical analysis of 35 patients with long-term follow-up,” Ophthalmologica, vol. 210, no. 2, pp. 90–94, 1996. View at Publisher · View at Google Scholar · View at Scopus
  39. G. P. Theodossiadis, C. Koutsandrea, and A. Tzonou, “A comparative study concerning the treatment of active toxoplasmic retinochoroiditis with argon laser and medication (follow-up 2–9 years),” Ophthalmologica, vol. 199, no. 2-3, pp. 77–83, 1989. View at Publisher · View at Google Scholar · View at Scopus
  40. P. D. Gormley, C. E. Pavesio, D. Minnasian, and S. Lightman, “Effects of drug therapy on Toxoplasma cysts in an animal model of acute and chronic disease,” Investigative Ophthalmology and Visual Science, vol. 39, no. 7, pp. 1171–1175, 1998. View at Google Scholar · View at Scopus
  41. S. Winterhalter, K. Severing, J. Stammen, A. K. Maier, E. Godehardt, and A. M. Joussen, “Does atovaquone prolong the disease-free interval of toxoplasmic retinochoroiditis?” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 248, no. 8, pp. 1187–1192, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Silveira, R. Belfort Jr., C. Muccioli et al., “The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis,” American Journal of Ophthalmology, vol. 134, no. 1, pp. 41–46, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. J. P. F. Felix, R. P. C. Lira, R. S. Zacchia, J. M. Toribio, M. A. Nascimento, and C. E. L. Arieta, “Trimethoprim-sulfamethoxazole versus placebo to reduce the risk of recurrences of Toxoplasma gondii retinochoroiditis: randomized controlled clinical trial,” American Journal of Ophthalmology, vol. 157, no. 4, pp. 762–766, 2014. View at Publisher · View at Google Scholar
  44. S. S. Vedula and Q. D. Nguyen, “Corticosteroids for ocular toxoplasmosis,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD007417, 2008. View at Publisher · View at Google Scholar · View at Scopus